IL148673A0 - Intranasal influenza virus vaccine - Google Patents

Intranasal influenza virus vaccine

Info

Publication number
IL148673A0
IL148673A0 IL14867300A IL14867300A IL148673A0 IL 148673 A0 IL148673 A0 IL 148673A0 IL 14867300 A IL14867300 A IL 14867300A IL 14867300 A IL14867300 A IL 14867300A IL 148673 A0 IL148673 A0 IL 148673A0
Authority
IL
Israel
Prior art keywords
influenza virus
virus vaccine
intranasal influenza
intranasal
vaccine
Prior art date
Application number
IL14867300A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922703.5A external-priority patent/GB9922703D0/en
Priority claimed from GBGB9922700.1A external-priority patent/GB9922700D0/en
Priority claimed from GB0016686A external-priority patent/GB0016686D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of IL148673A0 publication Critical patent/IL148673A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL14867300A 1999-09-24 2000-09-22 Intranasal influenza virus vaccine IL148673A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9922703.5A GB9922703D0 (en) 1999-09-24 1999-09-24 Vaccine
GBGB9922700.1A GB9922700D0 (en) 1999-09-24 1999-09-24 Vaccine
GB0016686A GB0016686D0 (en) 2000-07-06 2000-07-06 Novel vaccine
PCT/EP2000/009367 WO2001021151A1 (fr) 1999-09-24 2000-09-22 Vaccin intranasal contre les virus grippaux

Publications (1)

Publication Number Publication Date
IL148673A0 true IL148673A0 (en) 2002-09-12

Family

ID=27255796

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14867300A IL148673A0 (en) 1999-09-24 2000-09-22 Intranasal influenza virus vaccine

Country Status (23)

Country Link
US (2) US20050201946A1 (fr)
EP (2) EP1878424A3 (fr)
JP (1) JP4763197B2 (fr)
KR (1) KR20020038771A (fr)
CN (1) CN1391463A (fr)
AR (2) AR032597A1 (fr)
AT (1) ATE376825T1 (fr)
AU (1) AU764368B2 (fr)
BR (1) BR0014281A (fr)
CA (1) CA2383105C (fr)
CO (1) CO5280082A1 (fr)
CZ (1) CZ20021044A3 (fr)
DE (1) DE60036952T2 (fr)
ES (1) ES2293923T3 (fr)
HU (1) HUP0202846A3 (fr)
IL (1) IL148673A0 (fr)
MX (1) MXPA02003069A (fr)
MY (1) MY126588A (fr)
NO (1) NO20021431L (fr)
NZ (1) NZ517903A (fr)
PL (1) PL355287A1 (fr)
TR (1) TR200200776T2 (fr)
WO (1) WO2001021151A1 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
AU2002254901A1 (en) 2001-02-23 2002-10-03 Smithkline Beecham Biologicals S.A. Influenza vaccine formulations for intradermal delivery
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
NZ565512A (en) * 2005-08-02 2011-08-26 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102727885A (zh) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 包含颗粒佐剂和免疫增强剂组合的流感疫苗
CA2628152C (fr) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
US20080038294A1 (en) * 2006-03-22 2008-02-14 Kersten Alexander J Intranasal or inhalational administration of virosomes
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
CA2646349A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348A1 (fr) 2006-09-11 2019-03-20 Seqirus UK Limited Fabrication de vaccins contre le virus de la grippe sans utiliser d' ufs
CN101015691B (zh) * 2006-11-14 2010-08-25 中国医学科学院医学生物学研究所 重组噬菌体流感疫苗
CA2671629C (fr) 2006-12-06 2017-08-15 Novartis Ag Vaccins comprenant un antigene issu de quatre souches du virus grippal
CA2692200A1 (fr) 2007-06-27 2008-12-31 Novartis Ag Vaccins antigrippaux a faible teneur en additifs
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
WO2009081172A1 (fr) 2007-12-24 2009-07-02 Novartis Ag Dosages pour vaccins adsorbés contre la grippe
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
CN102046815A (zh) * 2008-06-02 2011-05-04 通用电气健康护理生物科学股份公司 用于病毒检测的方法
JP2012507272A (ja) 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
CU20080215A7 (es) 2008-11-19 2012-06-21 Inst Finlay Vacunas unitemporales
CA2752041A1 (fr) 2009-02-10 2010-08-19 Novartis Ag Vaccins contre l'influenza possedant des quantites accrues d'antigene h3
CA2752039A1 (fr) 2009-02-10 2010-08-19 Novartis Ag Regimes de vaccin antigrippal pour souches liees a une pandemie
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
BE1019643A3 (fr) 2009-04-27 2012-09-04 Novartis Ag Vaccins de protection contre la grippe.
US9072702B2 (en) 2009-05-21 2015-07-07 Novartis Ag Reverse genetics using non-endogenous pol I promoters
CA2800182A1 (fr) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Anticorps monoclonaux diriges contre le virus de la grippe, generes par administration cyclique, et leurs utilisations
JP5716297B2 (ja) 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
WO2011005772A1 (fr) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Procédés pour préparer des vésicules et formulations produites à partir de ces procédés
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9821052B2 (en) 2009-07-31 2017-11-21 Seqirus UK Limited Reverse genetics systems
EP2475385A1 (fr) 2009-09-10 2012-07-18 Novartis AG Vaccins combinés contre les maladies des voies respiratoires
US8883481B2 (en) 2009-10-20 2014-11-11 Novartis Ag Reverse genetics methods for virus rescue
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
BR112012020839A2 (pt) * 2010-02-18 2017-11-21 Sinai School Medicine vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
WO2011145081A1 (fr) 2010-05-21 2011-11-24 Novartis Ag Procédé de réarrangement des gènes du virus grippal
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
PL2575873T3 (pl) 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
WO2011154976A2 (fr) 2010-06-08 2011-12-15 Panacea Biotec Limited Vaccin antigrippal amélioré
WO2012006367A2 (fr) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions et méthodes pour traiter la grippe
CN101899101B (zh) * 2010-07-21 2012-07-25 中国检验检疫科学研究院 一种用于流感病毒亚单位疫苗研究的合成多肽
EP2605792B1 (fr) 2010-08-20 2014-12-10 Novartis AG Ensembles d'aiguilles solubles pour l'administration de vaccins contre la grippe
WO2012097346A1 (fr) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions et méthodes de traitement d'infections virales
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
CA2849434A1 (fr) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Vaccins contre le virus de la grippe et leurs utilisations
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
WO2013072768A2 (fr) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Dérivés synthétiques de mpl et ses utilisations
EP2802353A4 (fr) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Compositions et méthodes de traitement d'infections virales
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
JP6054883B2 (ja) 2012-03-02 2016-12-27 ノバルティス アーゲー インフルエンザウイルスの再集合
EP2822585B1 (fr) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Vaccination améliorée contre la grippe
WO2013182498A1 (fr) 2012-06-04 2013-12-12 Novartis Ag Test de sécurité amélioré
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
UY34506A (es) * 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
US9968670B2 (en) 2012-12-18 2018-05-15 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CA2897752A1 (fr) 2013-01-10 2014-07-17 Novartis Ag Compositions immunogenes comprenant un virus influenza et utilisations associees
CN111334530A (zh) 2013-03-13 2020-06-26 诺华股份有限公司 乙型流感病毒重配
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014180999A1 (fr) 2013-05-10 2014-11-13 Novartis Ag Évitement du risque de narcolepsie dans les vaccins contre la grippe
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
SG11201509985XA (en) 2013-06-06 2016-01-28 Novartis Ag Influenza virus reassortment
KR20160068972A (ko) 2013-11-15 2016-06-15 노파르티스 아게 잔여 세포 배양 불순물의 제거
EP3247389A4 (fr) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai Régimes de vaccination contre le virus de la grippe
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
JP6830070B2 (ja) 2015-07-07 2021-02-17 セキラス ユーケー リミテッドＳｅｑｉｒｕｓ ＵＫ Ｌｉｍｉｔｅｄ インフルエンザ効力アッセイ
CN105342982B (zh) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 经鼻给药的流感疫苗免疫制剂及其制备方法
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
PE20212322A1 (es) * 2019-02-15 2021-12-14 Serum Inst Of India Pvt Ltd Vacuna de influenza atenuada en vivo composicion y proceso de preparacion de los mismos
WO2020174288A1 (fr) 2019-02-25 2020-09-03 Seqirus UK Limited Vaccins contre la grippe multivalents à adjuvant multivalent
MX2022005513A (es) 2019-11-07 2022-06-08 Seqirus Uk Ltd Composiciones y metodos para producir una vacuna viral con tama?o de particula reducido.
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
CN113599513A (zh) * 2020-10-23 2021-11-05 青岛大学 一种适用于咽喉部接种的新型冠状病毒疫苗的制备方法及接种方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627873A (en) * 1967-06-09 1971-12-14 Arden Wesley Moyer Influenza vaccine with reduced pyrogenicity
US3874381A (en) * 1974-05-28 1975-04-01 Smithkline Corp Dual nozzle intranasal delivery device
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1291036C (fr) * 1986-04-23 1991-10-22 Edwin I. Stoltz Administration de medicaments par voie nasale
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
US5437267A (en) * 1993-08-03 1995-08-01 Weinstein; Allan Device for delivering aerosol to the nasal membranes and method of use
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
RU2086232C1 (ru) * 1994-06-03 1997-08-10 Уфимский научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Средство для интраназальной профилактики гриппа
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
IL138000A0 (en) * 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6506803B1 (en) * 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
WO2001098206A1 (fr) * 2000-06-22 2001-12-27 Rxkinetix, Inc. Composition de vecteur d'administration et procede pour l'administration d'antigenes et d'autres medicaments
US20040096463A1 (en) * 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
AU2002254901A1 (en) * 2001-02-23 2002-10-03 Smithkline Beecham Biologicals S.A. Influenza vaccine formulations for intradermal delivery
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use

Also Published As

Publication number Publication date
NZ517903A (en) 2003-10-31
AU7782500A (en) 2001-04-24
TR200200776T2 (tr) 2002-06-21
EP1878424A2 (fr) 2008-01-16
NO20021431D0 (no) 2002-03-21
US20090155309A1 (en) 2009-06-18
BR0014281A (pt) 2002-05-21
AU764368B2 (en) 2003-08-14
HUP0202846A3 (en) 2003-12-29
DE60036952D1 (de) 2007-12-13
EP1214054A1 (fr) 2002-06-19
MXPA02003069A (es) 2002-09-30
US20050201946A1 (en) 2005-09-15
DE60036952T2 (de) 2008-08-07
NO20021431L (no) 2002-04-24
CA2383105C (fr) 2010-01-26
JP4763197B2 (ja) 2011-08-31
JP2003509451A (ja) 2003-03-11
ES2293923T3 (es) 2008-04-01
MY126588A (en) 2006-10-31
EP1878424A3 (fr) 2008-04-09
HUP0202846A2 (hu) 2002-12-28
ATE376825T1 (de) 2007-11-15
KR20020038771A (ko) 2002-05-23
AR025750A1 (es) 2002-12-11
CZ20021044A3 (cs) 2002-08-14
AR032597A1 (es) 2003-11-19
CA2383105A1 (fr) 2001-03-29
CN1391463A (zh) 2003-01-15
PL355287A1 (en) 2004-04-05
WO2001021151A1 (fr) 2001-03-29
EP1214054B1 (fr) 2007-10-31
CO5280082A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
HUP0202846A3 (en) Intranasal influenza virus vaccine
HK1064958A1 (en) Vaccine against hpv
GB2337755B (en) Virus vaccine
HK1010833A1 (en) Influenza vaccine
HUP0303036A3 (en) Dna transfection system for the generation of infectious influenza virus
IL145043A0 (en) Vaccine
HUS1300072I1 (hu) Vakcina
HK1046243A1 (en) Aids virus vaccines using sendai virus vector
AU3328900A (en) Influenza virus hemagglutinin-binding peptides
AU3840101A (en) Cold-adapted equine influenza viruses
GB9915204D0 (en) Vaccine
IL144750A0 (en) Malaria vaccine
AU4957800A (en) Vaccine against isa virus
GB9906437D0 (en) Vaccine
GB9913327D0 (en) Vaccine
GB9917981D0 (en) Viral vaccine
GB9909072D0 (en) Vaccine
SI1436397T1 (sl) Cepivo proti virusu hepatitisa C
GB9925618D0 (en) Vaccine
GB9915106D0 (en) Vaccine
GB9922703D0 (en) Vaccine
GB9905511D0 (en) Vaccine
GB9915205D0 (en) Vaccine
GB9916677D0 (en) Vaccine
GB9917144D0 (en) Vaccine